Medical Advantages of Weight Loss Injections: A Focus on Tirazeptide and High Blood Pressure
Another noteworthy medical advantage has been linked to weight loss injections. Recent studies have highlighted that the medication, tirazeptide, can play a significant role in the reduction of high blood pressure. Last year, it was shown that weight loss drugs also reduce the risk of heart attack and stroke, which has led to further exploration of their health benefits. Despite these promising results, researchers are yet to determine whether the decrease in blood pressure is directly correlated to the weight loss triggered by the injections, or if it is an independent effect of the injections.
In Israel, one out of every five individuals suffers from high blood pressure, a condition often referred to as the “silent killer”. This is due to the fact that it typically doesn’t show any noticeable symptoms until it leads to severe damage in the body’s systems. Blood pressure refers to the force that is exerted on the blood vessels during the cardiac cycle.
Investigating the Effect of Weight Loss Injections on Blood Pressure
In recent studies, researchers have sought to examine the impact of weight loss injections on blood pressure levels. The first study, published in the American Journal of Hypertension, found that tirazeptide, sold under the brand names Zepbound for obesity and Monjaro for diabetes, significantly lowered blood pressure in obese adults who used it for nine months. This study is part of a larger clinical trial that had previously shown that a weekly injection of tirazeptide resulted in weight loss of up to 22% in overweight or obese adults. This impressive result prompted the American Food and Drug Administration (FDA) to approve the drug for the treatment of obesity.
The researchers enrolled 600 adults from the original clinical trial, all of whom had a body mass index of 27 or more (indicating obesity) and did not have type 2 diabetes. Some participants had normal blood pressure, while others had hypertension. Prior to starting the treatment, the participants’ blood pressure was monitored, and then again after nine months of weekly tirazeptide injections. The results indicated a significant decrease in systolic blood pressure – the blood pressure when the heart muscle contracts, which is the higher of the two blood pressure numbers. This outcome is a significant predictor of a heightened risk of heart disease.
Understanding the GLP1 Molecule and Its Role in Weight Loss Injections
The GLP1 molecule, which is the basis for weight loss injections, operates in a multi-systemic way: it increases the secretion of the hormone insulin from the pancreas, depending on the level of glucose in the blood. The higher the sugar level, the more insulin the molecule induces to be secreted, which then reduces sugar levels by promoting its absorption into the body’s cells.
Simultaneously, the drug decreases the secretion of another hormone called glucagon, which boosts the production of glucose and its release into the blood from the glucose stores in the liver. This hormone usually works when glucose levels drop, and the body protects itself by prompting the release of glucose from the liver into the blood. This results in additional control over the user’s blood sugar level. The GLP1 molecule also works in another path – it slows down the emptying of the stomach, leading to appetite suppression and an increase in the feeling of satiety through its effect on the hunger center in the brain. Through a mechanism that is yet to be fully understood, the molecule also reduces cravings for high-fat foods.
